GSA Capital Partners LLP reduced its position in shares of Insys Therapeutics, Inc. (NASDAQ:INSY) by 40.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,600 shares of the specialty pharmaceutical company’s stock after selling 32,400 shares during the quarter. GSA Capital Partners LLP owned about 0.07% of Insys Therapeutics worth $615,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Point72 Asset Management L.P. raised its holdings in Insys Therapeutics by 24.8% during the 1st quarter. Point72 Asset Management L.P. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $4,572,000 after purchasing an additional 86,373 shares during the last quarter. Credit Agricole S A raised its holdings in Insys Therapeutics by 20.0% during the 1st quarter. Credit Agricole S A now owns 374,400 shares of the specialty pharmaceutical company’s stock worth $3,935,000 after purchasing an additional 62,400 shares during the last quarter. Geode Capital Management LLC raised its holdings in Insys Therapeutics by 9.7% during the 1st quarter. Geode Capital Management LLC now owns 305,044 shares of the specialty pharmaceutical company’s stock worth $3,206,000 after purchasing an additional 26,913 shares during the last quarter. Strs Ohio raised its holdings in Insys Therapeutics by 40.0% during the 2nd quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock worth $2,213,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Insys Therapeutics by 1.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 156,471 shares of the specialty pharmaceutical company’s stock worth $1,980,000 after purchasing an additional 1,876 shares during the last quarter. 25.44% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/09/gsa-capital-partners-llp-sells-32400-shares-of-insys-therapeutics-inc-insy.html.

Shares of Insys Therapeutics, Inc. (NASDAQ INSY) opened at 8.86 on Monday. The firm’s 50-day moving average price is $9.22 and its 200 day moving average price is $10.99. Insys Therapeutics, Inc. has a one year low of $8.68 and a one year high of $15.06. The company’s market capitalization is $644.09 million.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.12. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm’s quarterly revenue was down 38.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 earnings per share. Analysts anticipate that Insys Therapeutics, Inc. will post ($0.29) earnings per share for the current year.

In other Insys Therapeutics news, CEO Saeed Motahari bought 5,500 shares of the stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the acquisition, the chief executive officer now owns 15,400 shares in the company, valued at approximately $137,368. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $8.93 per share, with a total value of $156,275.00. Following the completion of the acquisition, the insider now owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The disclosure for this purchase can be found here. 67.90% of the stock is owned by insiders.

INSY has been the subject of several recent research reports. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a report on Thursday, August 3rd. TheStreet cut Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price objective for the company in a report on Wednesday, July 12th. BidaskClub cut Insys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Piper Jaffray Companies set a $10.00 price objective on Insys Therapeutics and gave the stock a “hold” rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $13.25.

Insys Therapeutics Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics, Inc. (NASDAQ:INSY).

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.